



# The Oncomine Dx Express Test covers all clinically relevant biomarkers in NSCLC and the majority in other solid tumors



The Oncomine Dx Express Test gene targets per professional medical guidelines,<sup>2-3</sup> including ESCAT tier I for clinically relevant biomarkers and approved therapies



- NSCLC**  
ALK, BRAF, EGFR, MET, RET, ROS1, KRAS, NTRK1/2/3
- Breast cancer**  
PIK3CA, NTRK1/2/3, BRCA1/2\*, ERBB2
- Gastric cancer**  
ERBB2, NTRK1/2/3

- Cholangiocarcinoma**  
FGFR2, NTRK1/2/3, IDH1, BRAF
- Colorectal cancer**  
BRAF, NTRK1/2/3, ERBB2, KRAS, NRAS
- Skin cancer**  
BRAF, NTRK1/2/3, NRAS, ALK, ROS1
- Thyroid cancer**  
NTRK1/2/3, ALK, RET, BRAF

- Ovarian cancer**  
BRCA1/2, NTRK1/2/3, ERBB2
- Hepatocellular carcinoma**  
NTRK1/2/3
- Pancreatic adenocarcinoma**  
NTRK1/2/3, ALK, BRCA1/2\*, NRG1, ROS1, RET, KRAS, STK11, TP53, FGFR2

\* BRCA1/2 and MSI-H are not covered by the Oncomine Dx Express Test.

1. Mosele F et al. *Ann Oncol*. 2020 Nov 1;31(11):1491-1505.  
2. NCCN Clinical Practice Guidelines in Oncology (Accessed May 2022).  
3. College of American Pathologists/Protocol and Guidelines/Cancer Reporting and Biomarker Reporting Protocols (Accessed May 2022).